Psyence BioMed Obtains 250:1 Share Consolidation Authority and Auditor Approval
Psyence BioMed shareholders approved election of all director nominees, appointed MNP LLP as auditors, and authorized share consolidation authority. The board may implement a share consolidation of up to 250:1 common shares at its discretion, subject to regulatory and exchange approvals with further disclosure upon determination.
1. Shareholder Voting Results
On February 12, Psyence BioMed shareholders unanimously elected all director nominees to serve until the next annual meeting and approved the appointment of MNP LLP as the company’s auditors, authorizing the board to set auditors’ remuneration for the ensuing year.
2. Share Consolidation Authority
Shareholders granted the board a special resolution to consolidate up to 250:1 of the company’s issued and outstanding common shares, with any consolidation to be executed at a time and ratio determined by the board and subject to applicable regulatory and exchange approvals, with further disclosure upon implementation.